Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Annovis Bio, Inc.ANVS · Entity 7001 | Vice President, Finance | June 16, 2025 | June 18, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Annovis Bio, Inc.
Report date June 16, 2025 · Filed June 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 500 |
Reported balance
After 2025-06-16 transaction · row 1
1 source rowRow 1 · 2025-06-16 · Grant · Acquired 500 · Balance 500 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2025 Filed Jun 18, 2025 16:05 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | GrantCommon Stock | 500 | $2.90 | $1,450.00 |
DisclosureSEC source: 0001104659-25-060632 · tm2518255-1_4seq1.xml · nonDerivative · entry 1 Walsh Andrew · CIK 0002068849 · Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.